A recent study indicates that people who come off blockbuster slimming jabs like Wegovy and Mounjaro can put back on lost weight at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Published data in a prominent medical journal demonstrates that while overweight people often shed about a fifth of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Users purchasing these medications need to be cognizant of the danger of rapid weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
That rate of regain means a reversion to original weight in about 18 months.
Weighing Treatments
The research, which reviewed 37 of studies involving thousands of patients, contrasted the outcomes of the injectable medications with older methods.
The team point out that individuals who lose weight through lifestyle changes alone usually experience a slower weight regain—around 0.1 kg a month—post-intervention.
Explaining the Rapid Regain
Experts propose the mechanism of the drugs explains the accelerated weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels far above than normal may cause the system to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement leads to hunger is uncontrolled, making overeating a significant risk."
A Chronic Issue?
Medical guidelines advise the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals say that, due to the high risk of relapse, the treatment should be considered life-long.
This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the chronic character of obesity," similar to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication describe a powerful return of cravings.
"It was like something that goes on and you're instantly starving," said a patient.
This challenge is exacerbated if individuals have not adopted sustainable dietary or behavioural changes during treatment.
Growing Adoption
Recent estimates suggest that a significant number of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Use is more common among women than males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, experts caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent solution and maintained weight loss relies on integrated lifestyle management.
